AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22674565 — intervention group
Group type: EXPERIMENTAL
Intervention: Kouk Sun Do (KSD) exercise sessions (10 sessions, 70 minutes each, three times per week for 4 weeks)
Number of subjects: 30
Study 22674565 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 30
Study 22674565 — intervention group
Group type: EXPERIMENTAL
Intervention: Kouk Sun Do (KSD) exercise sessions
Number of subjects: 30
Study 21756760 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐Viewer system under a direct vision
Number of subjects: 84
Study 21756760 — intervention group
Group type: COMPARATOR
Intervention: Conventional operations
Number of subjects: 84
Study 19130489 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week treatment trial
Number of subjects: 116
Study 16867921 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with dysthymia
Number of subjects: 81
Study 16867921 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with current depressive disorders
Number of subjects: 81
Study 16867921 — intervention group
Group type: COMPARATOR
Intervention: Women without current depressive disorders
Number of subjects: 81
Study 14758149 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cells stored < or =5 days (10 patients)
Number of subjects: 22
Study 14758149 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cells stored > or =20 days (12 patients)
Number of subjects: 22
Study 11059996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management (ICM)
Number of subjects: 545
Study 11059996 — intervention group
Group type: COMPARATOR
Intervention: Standard case management (C)
Number of subjects: 545
Study 11004136 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dietary counseling aiming for fat intake of 30% to 35% of daily energy, saturated/monounsaturated/polyunsaturated fatty acid ratio of 1:1:1, cholesterol intake of <200 mg/d
Number of subjects: 1062
Study 11004136 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 1062
Study 8968265 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGF-1 concentrations in women
Number of subjects: 108
Study 8968265 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGF-1 concentrations in men
Number of subjects: 108
Study 8968265 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthyretin concentrations in women
Number of subjects: 108
Study 8968265 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthyretin concentrations in men
Number of subjects: 108
Study 8968265 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin concentrations
Number of subjects: 108
Study 8968265 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 108
Study 1519481 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN‐alpha) at a dose of 3.0 x 10(6) IU/day for 28 days (open trial)
Number of subjects: 16
Study 1519481 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN‐alpha) at a dose of 3.0 x 10(6) IU/day (randomized trial)
Number of subjects: 16
Study 1519481 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (IFN‐alpha) at doses of 3.0 x 10(6), 1.0 x 10(6) or 0.3 x 10(6) IU/day (randomized trial)
Number of subjects: 16
Study 6507507 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring blood glucose at home
Number of subjects: 100
Study 6507507 — intervention group
Group type: COMPARATOR
Intervention: Hospital care
Number of subjects: 100
Study 29691233 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μmol oral BSE‐SFN daily for 28 days
Number of subjects: 17
Study 29691233 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μmol oral BSE‐SFN daily for 28 days
Number of subjects: 17
Study 29691233 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μmol oral BSE‐SFN daily for 28 days
Number of subjects: 17
Study 29691233 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of proinflammatory cytokines
Number of subjects: 17
Study 29691233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor suppressor decorin
Number of subjects: 17
Study 26708636 — intervention group
Group type: EXPERIMENTAL
Intervention: Single caffeinated energy shot
Number of subjects: 26
Study 26708636 — intervention group
Group type: COMPARATOR
Intervention: Multiple caffeinated energy shots
Number of subjects: 26
Study 26708636 — intervention group
Group type: COMPARATOR
Intervention: Caffeinated energy shots
Number of subjects: 26
Study 24744162 — intervention group
Group type: COMPARATOR
Intervention: UFT (300 mg/m²) plus leucovorin (75 mg/day) for 6 months (control group)
Number of subjects: 1071
Study 24744162 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (300 mg/m²) plus leucovorin (75 mg/day) for 18 months (study group)
Number of subjects: 1071
Study 22172982 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent visual task during text composition
Number of subjects: 0
Study 22172982 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard composition condition with written trace
Number of subjects: 0
Study 22172982 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition with visual noise
Number of subjects: 0
Study 22172982 — intervention group
Group type: COMPARATOR
Intervention: Condition with suppressed written trace
Number of subjects: 0
Study 20451668 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation phase cognitive therapy (C-CT)
Number of subjects: 523
Study 20451668 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (FLX)
Number of subjects: 523
Study 20451668 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 523
Study 17400143 — intervention group
Group type: EXPERIMENTAL
Intervention: Prayer during surgery
Number of subjects: 78
Study 17400143 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation technique during surgery
Number of subjects: 78
Study 17400143 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 78
Study 15759292 — intervention group
Group type: EXPERIMENTAL
Intervention: (1)H NMR spectroscopy
Number of subjects: 30
Study 15759292 — intervention group
Group type: COMPARATOR
Intervention: Other common bacteria (Escherichia coli, Klebsiella pneumonia, Enterobacter aerogenes, Acinetobacter baumanii, Proteus mirabilis, Citrobacter frundii, Enterococcus faecalis, Streptococcus gp B, Staphylococcus aureus)
Number of subjects: 30
Study 12036817 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 n‐3 fatty acid‐enriched egg yolks/wk
Number of subjects: 161
Study 12036817 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 regular egg yolks/wk
Number of subjects: 161
Study 12036817 — intervention group
Group type: COMPARATOR
Intervention: No dietary intervention
Number of subjects: 161
Study 9572324 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg once daily
Number of subjects: 0
Study 9572324 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0
Study 9572324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9572324 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0
Study 9572324 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0
Study 7626544 — intervention group
Group type: EXPERIMENTAL
Intervention: 65 deg, full depth-cue condition
Number of subjects: 64
Study 7626544 — intervention group
Group type: EXPERIMENTAL
Intervention: 65 deg, reduced depth-cue condition
Number of subjects: 64
Study 7626544 — intervention group
Group type: COMPARATOR
Intervention: Frontoparallel condition
Number of subjects: 64
Study 7626544 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic and multielement patterns
Number of subjects: 64
Study 7626544 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ms and 1 s exposures
Number of subjects: 64
Study 2614884 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO‐3708 (thromboxane A2 antagonist)
Number of subjects: 0
Study 2614884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30066672 — intervention group
Group type: EXPERIMENTAL
Intervention: SUPRAFLEX sirolimus‐eluting stent (SES)
Number of subjects: 1430
Study 30066672 — intervention group
Group type: COMPARATOR
Intervention: XIENCE everolimus‐eluting stent (EES)
Number of subjects: 1430
Study 30268481 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic index (PI) lower than the signature median (n=92)
Number of subjects: 195
Study 30268481 — intervention group
Group type: COMPARATOR
Intervention: Prognostic index (PI) higher than the signature median (n=103)
Number of subjects: 195
Study 26661723 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial smoking ban
Number of subjects: 375
Study 26661723 — intervention group
Group type: COMPARATOR
Intervention: No smoking ban
Number of subjects: 375
Study 24751406 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy (DE) imaging
Number of subjects: 10
Study 24751406 — intervention group
Group type: COMPARATOR
Intervention: Single energy (SE) imaging
Number of subjects: 10
Study 24751406 — intervention group
Group type: COMPARATOR
Intervention: Conventional kV imaging
Number of subjects: 10
Study 22064878 — intervention group
Group type: EXPERIMENTAL
Intervention: FATaintPHAT Web-based computer-tailored intervention
Number of subjects: 883
Study 22064878 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 883
Study 18615332 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine 16 mg tid
Number of subjects: 120
Study 18615332 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine 24 mg bid
Number of subjects: 120
Study 18615332 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 17989709 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy without stem cell transplant
Number of subjects: 1053
Study 17989709 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients <20 years old
Number of subjects: 1053
Study 17989709 — intervention group
Group type: COMPARATOR
Intervention: Patients >20 years old
Number of subjects: 1053
Study 15950639 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose (SD) protocol for GnRH antagonist (cetrorelix)
Number of subjects: 61
Study 15950639 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose (MD) protocol for GnRH antagonist (cetrorelix)
Number of subjects: 61
Study 15950639 — intervention group
Group type: COMPARATOR
Intervention: Long protocol (LP) for GnRH agonist (buserelin)
Number of subjects: 61
Study 12131064 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple pain intensity measurements (average pain intensity measured 3 times a day over 4 days)
Number of subjects: 54
Study 12131064 — intervention group
Group type: EXPERIMENTAL
Intervention: Single pain rating (recalled average pain as assessed by the patient)
Number of subjects: 54
Study 10351969 — intervention group
Group type: EXPERIMENTAL
Intervention: TUNEL-positive myocytes in DCM specimens
Number of subjects: 20
Study 10351969 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of TUNEL-positive myocytes per section in DCM
Number of subjects: 20
Study 10351969 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrastructural analysis of myocytes in DCM
Number of subjects: 20
Study 10351969 — intervention group
Group type: EXPERIMENTAL
Intervention: Taq polymerase-based DNA in situ ligation assay
Number of subjects: 20
Study 10351969 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of proliferating cell nuclear antigen in TUNEL-positive myocytes
Number of subjects: 20
Study 10351969 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of Ki-67 in TUNEL-positive myocytes
Number of subjects: 20
Study 7579007 — intervention group
Group type: EXPERIMENTAL
Intervention: epalrestat (150 mg/day, 50 mg tid, po)
Number of subjects: 196
Study 7579007 — intervention group
Group type: COMPARATOR
Intervention: placebo (9 mg/day, 3 mg tid, po)
Number of subjects: 196
Study 1770154 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg daily
Number of subjects: 73
Study 1770154 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 10 mg daily
Number of subjects: 73
Study 1770154 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 20 mg daily
Number of subjects: 73
Study 1770154 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (all doses)
Number of subjects: 73
Study 7102708 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical acyclovir
Number of subjects: 0
Study 30690714 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate receipt of an individualized survivorship care plan (SCP)
Number of subjects: 127
Study 30690714 — intervention group
Group type: COMPARATOR
Intervention: Delayed receipt of an individualized survivorship care plan (SCP)
Number of subjects: 127
Study 30690714 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms combined (immediate and delayed SCP)
Number of subjects: 127
Study 27884499 — intervention group
Group type: EXPERIMENTAL
Intervention: Open chain resisted band exercises (OC)
Number of subjects: 120
Study 27884499 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed chain exercises (CC)
Number of subjects: 120
Study 27884499 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally loaded range of movement exercises (ROM)
Number of subjects: 120
Study 26337820 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat (LF) diet
Number of subjects: 27
Study 26337820 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic-load (LGL) diet
Number of subjects: 27
Study 23384734 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P (pain assessment)
Number of subjects: 300
Study 21386042 — intervention group
Group type: EXPERIMENTAL
Intervention: milieu language teaching (MLT)
Number of subjects: 57
Study 21386042 — intervention group
Group type: COMPARATOR
Intervention: broad target recasts (BTR)
Number of subjects: 57
Study 19679384 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese Medicine (TCM) recipe (Panax, 520 mg; Astragalus membranaceous Bunge, 520 mg; Masnetitum, 840 mg; Ostrea gigas Thumb, 470 mg; Thinleaf Milkwort Root Radix Polygalae, 450 mg; Os Draconis, 470 mg) administered as a diet supplement for 60 days.
Number of subjects: 14
Study 19679384 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what intervention was given).
Number of subjects: 14
Study 17565930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin ointment administered twice daily for 5 days every 4 weeks
Number of subjects: 49
Study 17565930 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mupirocin treatment)
Number of subjects: 49
Study 17565930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin ointment
Number of subjects: 49
Study 15633941 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 246
Study 15633941 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 246
Study 11452572 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuband worn on the wrist
Number of subjects: 25
Study 11452572 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuband worn on the arm
Number of subjects: 25
Study 11452572 — intervention group
Group type: COMPARATOR
Intervention: Control (no Acuband)
Number of subjects: 25
Study 11452572 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuband worn on the wrist or arm
Number of subjects: 25
Study 9670693 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatments in addition to standard treatment (allopurinol, NSAIDs, glucocorticosteroids)
Number of subjects: 38
Study 9670693 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (allopurinol, NSAIDs, glucocorticosteroids)
Number of subjects: 38
Study 7810077 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet supplemented with ketoanalogs of essential amino acids and a low-phosphate drink from casein-free protein (Group I)
Number of subjects: 36
Study 7810077 — intervention group
Group type: COMPARATOR
Intervention: Mixture of essential and non-essential amino acids of egg white (Group II)
Number of subjects: 36
Study 2929157 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 53
Study 2929157 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (chemo and radiotherapy)
Number of subjects: 53
Study 2929157 — intervention group
Group type: COMPARATOR
Intervention: Irradiation
Number of subjects: 53
Study 31199555 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based Affect Management Intervention (FAMI)
Number of subjects: 47
Study 31199555 — intervention group
Group type: COMPARATOR
Intervention: Health Promotion Intervention (HPI)
Number of subjects: 47
Study 29520926 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual CBT
Number of subjects: 1253
Study 29520926 — intervention group
Group type: COMPARATOR
Intervention: Group CBT
Number of subjects: 1253
Study 29520926 — intervention group
Group type: COMPARATOR
Intervention: Guided parent-led CBT
Number of subjects: 1253
Study 26948366 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with procarbazine, lomustine, vincristine (PCV)
Number of subjects: 0
Study 26948366 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with temozolomide
Number of subjects: 0
Study 26948366 — intervention group
Group type: COMPARATOR
Intervention: Delaying radiotherapy and treatment with chemotherapy only
Number of subjects: 0
Study 24449169 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Hz stimulation
Number of subjects: 0
Study 24449169 — intervention group
Group type: COMPARATOR
Intervention: 130 Hz stimulation
Number of subjects: 0
Study 23734703 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement with care management support
Number of subjects: 0
Study 23734703 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement with provider education
Number of subjects: 0
Study 23734703 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement only
Number of subjects: 0
Study 23734703 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all three interventions
Number of subjects: 0
Study 20416080 — intervention group
Group type: EXPERIMENTAL
Intervention: CDA's CVD Toolkit (intervention arm)
Number of subjects: 800
Study 18629552 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoosteotomy
Number of subjects: 90
Study 18629552 — intervention group
Group type: COMPARATOR
Intervention: Conventional saw and chisel osteotomy
Number of subjects: 90
Study 15926947 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichoderma harzianum exposure (approximately 350,000 spores/m3 for 6 min)
Number of subjects: 8
Study 15926947 — intervention group
Group type: COMPARATOR
Intervention: Placebo exposure
Number of subjects: 8
Study 15926947 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillium chrysogenum exposure (approximately 600,000 spores/m3 for 6 min)
Number of subjects: 8
Study 11934715 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 ml/kg of 10 mM GSNO
Number of subjects: 20
Study 11934715 — intervention group
Group type: COMPARATOR
Intervention: Phosphate buffered saline (placebo)
Number of subjects: 20
Study 10656476 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered food frequency questionnaire (FFQ) reviewed by a nutritionist
Number of subjects: 324
Study 10656476 — intervention group
Group type: COMPARATOR
Intervention: Self-administered food frequency questionnaire (FFQ) without nutritionist review
Number of subjects: 324
Study 8652950 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG or TMS
Number of subjects: 24
Study 8652950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2328304 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual dimenhydrinate (50 mg)
Number of subjects: 8
Study 2328304 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dimenhydrinate (50 mg)
Number of subjects: 8
Study 2328304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dimenhydrinate (50 mg)
Number of subjects: 8
Study 7370144 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 56
Study 7370144 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate
Number of subjects: 56
Study 31158718 — intervention group
Group type: EXPERIMENTAL
Intervention: MI+CBT (Motivational Interviewing + Cognitive Behavioral Therapy)
Number of subjects: 186
Study 31158718 — intervention group
Group type: COMPARATOR
Intervention: SC+CBT (Supportive Counselling + Cognitive Behavioral Therapy)
Number of subjects: 186
Study 31158718 — intervention group
Group type: EXPERIMENTAL
Intervention: MI+CBT
Number of subjects: 186
Study 31158718 — intervention group
Group type: COMPARATOR
Intervention: SC+CBT
Number of subjects: 186
Study 28130918 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg
Number of subjects: 305
Study 28130918 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 1,000 mg
Number of subjects: 305
Study 28130918 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Number of subjects: 305
Study 26210606 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of alcohol (.6 g/kg)
Number of subjects: 114
Study 26210606 — intervention group
Group type: COMPARATOR
Intervention: Soft drink
Number of subjects: 114
Study 26210606 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar-lab environment
Number of subjects: 114
Study 26210606 — intervention group
Group type: COMPARATOR
Intervention: Sterile lab environment
Number of subjects: 114
Study 23766507 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated obstructive hypopnea (inspiration through a threshold load)
Number of subjects: 10
Study 23766507 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated obstructive apnea (Mueller maneuver)
Number of subjects: 10
Study 23766507 — intervention group
Group type: EXPERIMENTAL
Intervention: End‐expiratory central apnea
Number of subjects: 10
Study 20937602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal carboplatin in combination with intravenous weekly dose-dense paclitaxel
Number of subjects: 746
Study 20937602 — intervention group
Group type: COMPARATOR
Intervention: Intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel
Number of subjects: 746
Study 19448846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) for 16 weeks
Number of subjects: 24
Study 19448846 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (VEN) for 16 weeks
Number of subjects: 24